Literature DB >> 30120106

Isoproterenol-induced beta-2 adrenergic receptor activation negatively regulates interleukin-2 signaling.

Blanca E Ruiz-Medina1, Denisse A Cadena-Medina1, Edmundo Esparza1, Amy J Arrieta1, Robert A Kirken2.   

Abstract

Regulation of intracellular signaling pathways in lymphocytes is critical for cell homeostasis and immune response. Interleukin-2 (IL-2), a key regulator of lymphocytes, signals following receptor-ligand engagement and subsequent recruitment and activation of effector proteins including JAKs and STATs. Lymphocytes can also be regulated by the central nervous system through the β2 adrenergic receptor (β2AR) pathway which can affect cell trafficking, proliferation, differentiation, and cytokine production. The cross-talk between these two signaling pathways represents an important mechanism that has yet to be fully elucidated. The present study provides evidence for communication between the IL-2 receptor (IL-2R) and β2AR. Treatment of human lymphoid cell lines with the β2AR agonist isoproterenol (ISO) alone increased cAMP levels and mediated a stimulatory response by activating AKT and ERK to promote cell viability. Interestingly, ISO activation of β2AR also induced threonine phosphorylation of the IL-2Rβ. In contrast, ISO treatment prior to IL-2 stimulation produced an inhibitory signal that disrupted IL-2 induced activation of the JAK/STAT, MEK/ERK, and PI3K pathways by inhibiting the formation of the IL-2R beta-gamma chain complex, and subsequently cell proliferation. Moreover, γc-family cytokines-mediated STAT5 activation was also inhibited by ISO. These results suggest a molecular mechanism by which β2AR signaling can both stimulate and suppress lymphocyte responses and thus explain how certain therapeutic agents, such as vasodilators, may impact immune responsiveness.
© 2018 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  adrenergic receptor; beta-2 adrenergic receptor; cytokine receptors; interleukin-2; signal transducers and activators of transcription; signaling

Mesh:

Substances:

Year:  2018        PMID: 30120106     DOI: 10.1042/BCJ20180503

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  7 in total

Review 1.  Role of adrenergic receptor signalling in neuroimmune communication.

Authors:  Sushanta Chhatar; Girdhari Lal
Journal:  Curr Res Immunol       Date:  2021-11-25

2.  PlexinA1 activation induced by β2-AR promotes epithelial-mesenchymal transition through JAK-STAT3 signaling in human gastric cancer cells.

Authors:  Ying Liu; Yanhui Hao; Hanzheng Zhao; Ying Zhang; Die Cheng; Li Zhao; Yuqiao Peng; Yanjie Lu; Yuhong Li
Journal:  J Cancer       Date:  2022-04-18       Impact factor: 4.478

Review 3.  Regulation of natural killer cell activity by glucocorticoids, serotonin, dopamine, and epinephrine.

Authors:  Silvia Capellino; Maren Claus; Carsten Watzl
Journal:  Cell Mol Immunol       Date:  2020-06-05       Impact factor: 11.530

4.  TPD7 inhibits the growth of cutaneous T cell lymphoma H9 cell through regulating IL-2R signalling pathway.

Authors:  Man Zhu; Liu Yang; Xianpeng Shi; Zhengyan Gong; Runze Yu; Dongdong Zhang; Yanmin Zhang; Weina Ma
Journal:  J Cell Mol Med       Date:  2019-11-19       Impact factor: 5.310

Review 5.  Dysfunction of the Autonomic Nervous System and its Role in the Pathogenesis of Septic Critical Illness (Review).

Authors:  Y Y Kiryachkov; S A Bosenko; B G Muslimov; M V Petrova
Journal:  Sovrem Tekhnologii Med       Date:  2020-08-27

6.  Endogenously produced catecholamines improve the regulatory function of TLR9-activated B cells.

Authors:  Nadine Honke; Torsten Lowin; Birgit Opgenoorth; Namir Shaabani; Alexander Lautwein; John R Teijaro; Matthias Schneider; Georg Pongratz
Journal:  PLoS Biol       Date:  2022-01-24       Impact factor: 8.029

7.  β2-Adrenergic Receptor Expression and Intracellular Signaling in B Cells Are Highly Dynamic during Collagen-Induced Arthritis.

Authors:  Nadine Honke; Clemens J Wiest; Georg Pongratz
Journal:  Biomedicines       Date:  2022-08-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.